FLT3 and acute myeloid leukemia: Deploying this strategy, several studies have shown promising results in in vitro studies.[26,34,40] A study by Wang et al unveiled that palbociclib and SU14813, a FLT3 inhibitor, synergistically enhanced apoptotic activity in FLT3-ITD-positive AML cell lines, MV4-11 and MOLM13, achieving combination indices of 0.78 and 0.67, respectively.[34] Interestingly, this synergism did not extend to primary AML blasts.